CBL antibody

Este producto es parte de CBL - E3 ubiquitin protein ligase
Product Graph
Contáctenos para saber el precio

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
CBL antibody
category
Primary Antibodies
provider
FineTest
reference
FNab01317
tested applications
ELISA, WB, IHC

Description

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Documents del producto

Instrucciones
Descargar
Data sheet
Descargar

Product specifications

Category
Primary Antibodies
Immunogen Target
Cas-Br-M (murine) ecotropic retroviral transforming sequence (CBL)
Host
Rabbit
Reactivity
Human, Mouse
Recommended Dilution
WB: 1:500 - 1:2000; IHC: 1:50 - 1:100
Clonality
polyclonal
Conjugation
Unconjugated
Isotype
IgG
Observed MW
117 kDa
Purity
≥95% as determined by SDS-PAGE
Purification
Immunogen affinity purified
Size 1
100µg
Form
liquid
Tested Applications
ELISA, WB, IHC
Storage
PBS with 0.02% sodium azide and 50% glycerol pH 7.3, -20℃ for 12 months (Avoid repeated freeze / thaw cycles.)
UniProt ID
P22681
Gene ID
867
Alias
CBL, C-CBL2, FRA11B, NSLL, RNF55
Background
Antibody anti-CBL
Status
RUO
Note
Mol. Weight 117 kDa

Descripción

CBL is an E3 ubiquitin ligase that plays a crucial role in regulating signal transduction pathways, particularly those associated with receptor tyrosine kinases (RTKs) like the epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor (PDGFR). CBL mediates the ubiquitination of target proteins, leading to their degradation via the proteasome, and regulates the receptor's internalization and downregulation. This process ensures the proper termination of signaling, which is important for cellular processes such as growth, differentiation, and survival. Dysregulation of CBL activity has been implicated in various cancers, as uncontrolled signaling due to deficient ubiquitination can result in unchecked cell proliferation and survival.

Related Products

FNab01317

CBL antibody

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia, and expansion of CGG repeats in the 5' UTR has been associated with Jacobsen syndrome. Mutations in this gene are also the cause of Noonan syndrome-like disorder.

Ver Producto
P2114

Recombinant Human CBL

Ver Producto
abx037845

E3 Ubiquitin-Protein Ligase CBL (CBL) Antibody

Rabbit Polyclonal against the CBL protein.

Ver Producto